Insulet (PODD) Akcia Kurs
Insulet Kurs
Tržby rástli o 41,6 % ročne za posledných 19 rokov na 2,71 Miliarda USD. Zisk na akciu rástol o 81,5 % ročne za posledných 7 rokov. čistá marža spoločnosti Insulet je teraz 9,1 %, stúpla z 1,5 % pred niekoľkými rokmi. Medián cieľovej ceny analytikov je 180,00 USD, teda nad aktuálnu cenu o 22,3 %. Z 32 analytikov 19 odporúča nákup — celkový konsenzus je Kúpiť.
Cena akcie Insulet
Tieto dáta cez Eulerpool API
100 000 požiadaviek/mes. zadarmo · bez karty
Akcia Insulet a analýza akcií
Často kladené otázky o akcii Insulet
The business model of Insulet Corp revolves around the development and commercialization of innovative medical devices for individuals with diabetes. Insulet is known for its flagship product, the Omnipod Insulin Management System, which is a tubeless insulin pump. This system is designed to provide continuous subcutaneous insulin delivery with customizable insulin plans and improved convenience for users. Insulet Corp focuses on helping diabetes patients manage their condition effectively and ensuring a better quality of life. With their unique and advanced technology, Insulet continues to make significant contributions to the diabetes healthcare industry.
Insulet Corp is primarily active in the healthcare industry, specifically in the medical devices sector.
The main competitors of Insulet Corp in the market are Medtronic plc, Tandem Diabetes Care, Inc., and Dexcom, Inc. These companies operate in the same industry sector and offer similar products and services. Medtronic plc is a multinational medical device company, Tandem Diabetes Care, Inc. specializes in insulin pumps, and Dexcom, Inc. provides continuous glucose monitoring systems. These competitors pose challenges to Insulet Corp in terms of market share and product innovation. Competing with these industry leaders, Insulet Corp strives to differentiate itself through its Omnipod System, a unique tubeless insulin delivery system.
Insulet Corp is a leading medical technology company headquartered in Massachusetts, United States. Founded in 2000, Insulet is focused on improving the lives of individuals with diabetes through the development and manufacturing of innovative insulin delivery systems. The company is renowned for its flagship product, the Omnipod Insulin Management System, which offers patients a unique tubeless and wireless insulin pump experience. Insulet has a rich history of achievement and continuous growth, earning recognition for its dedication to patient-centric solutions. With a strong commitment to advancing diabetes care, Insulet Corp has positioned itself as a trusted and reliable provider in the medical technology industry.
Insulet Corp has achieved several significant milestones in its history. One of the notable achievements is the development and introduction of the Omnipod System, a tubeless insulin delivery system that has revolutionized diabetes management. This innovative product has gained wide acceptance and has positively impacted the lives of many patients. Additionally, Insulet Corp has successfully expanded its global presence, securing regulatory approvals in various countries and establishing partnerships with healthcare providers worldwide. The company has also demonstrated consistent financial growth and market success, solidifying its position as a leader in the diabetes technology industry.
Insulet Corp primarily operates in the United States, Canada, Europe, and the Middle East.
Insulet Corp is a renowned company in the stock market known for its values and corporate philosophy. The company aims to improve the lives of people with diabetes through innovative and reliable technologies. Insulet Corp values patient-centricity by providing user-friendly and discreet products like the Omnipod System. Their corporate philosophy revolves around continuous innovation, teamwork, and a commitment to making a difference in diabetes management. Insulet Corp's vision is to empower individuals with diabetes to live life to the fullest, offering them better control, flexibility, and convenience. With a dedicated focus on diabetes care, Insulet Corp sets itself apart in the market, making it a highly regarded company among investors.
Analytici aktuálne stanovujú priemernú cieľovú cenu 185,18 USD pre akciu Insulet (medián: 180,00 USD), teda +25,8 % voči poslednej cene. Konsenzus vychádza z 32 hodnotení.
32 analytikov aktuálne hodnotí akciu Insulet: 19 odporúča kúpiť, 13 držať a 0 predať. Na 2026 analytici očakávajú, že Insulet dosiahne tržby 3,29 Miliarda USD a zisk na akciu 6,62 USD.
Pri aktuálnom kurze sa akcia Insulet obchoduje za 131,34 EUR (147,23 USD).
Akcia Insulet (PODD) je kótovaná na 5 burzách, okrem iného: NASDAQ (PODD), SIX (Zürich) (GOV.SW), Frankfurt (GOV.F), München (GOV.MU), Düsseldorf (GOV.DU).
Insulet Corporation is a company specializing in the development and manufacturing of personalized insulin delivery systems. The company is headquartered in Acton, Massachusetts, USA and was founded in 2000.
Tržby očakávané od Insulet sú 3,29 Miliarda USD. Táto hodnota je založená na aktuálnych finančných údajoch a odráža obchodnú výkonnosť spoločnosti.
Zisk očakávané od Insulet je 467,79 Milión USD. Čistý zisk odráža ziskovosť spoločnosti po odpočítaní všetkých nákladov.
Pomer ceny k zisku (P/E) Insulet je v súčasnosti 22,24. P/E pomer porovnáva aktuálnu cenu akcie s ziskom na akciu a pomáha investorom pochopiť ocenenie akcie Insulet.
Pomer ceny k tržbám (P/S) Insulet je v súčasnosti 3,16. P/S pomer porovnáva tržnú kapitalizáciu s ročnými tržbami a slúži ako metryka ocenenia akcie Insulet.
Skóre kvality AlleAktien pre Insulet je 6/10.
ISIN Insulet je US45784P1012. ISIN (Medzinárodné číslo identifikácie cenného papiera) je globálne jedinečný identifikátor cenných papierov.
WKN Insulet je A0MQX8. WKN (Wertpapierkennnummer) je šesťmiestny nemecký identifikačný kód cenného papiera.
Ticker Insulet je PODD. Tento burzovný symbol sa používa na obchodovanie akcií Insulet na burze.
Insulet akcia
Insulet Peer Group
Insulet Ticker
Insulet FIGI
Ďalšie kľúčové údaje a analýzy Insulet v podrobnom prieskume
Naša analýza akcií spoločnosti Insulet obsahuje dôležité finančné ukazovatele, ako sú tržby, zisk, P/E pomer, P/S pomer, EBIT, ako aj informácie o dividende. Okrem toho skúmame aspekty, ako sú akcie, trhová kapitalizácia, dlhy, vlastné imanie a záväzky spoločnosti Insulet. Ak hľadáte podrobnejšie informácie k týmto témam, na našich podstránkach vám ponúkame podrobné analýzy: